Public Launch of SISAQOL-IMI Recommendations Event description: The Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints – Innovative Medicines Initiative (SISAQOL-IMI) consortium will hold its public launch on February 4, 2025, during the concluding Consensus Meeting. This event is open to external stakeholders and will feature key highlights from the recommendations, [...]
SISAQOL-IMI Receives the 2024 SPAIG Award On Tuesday, August 6th, 2024 On Tuesday, August 6th, 2024, SISAQOL-IMI (Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials – IMI) was awarded the prestigious Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award [...]
On the 23-24 of May, 2023 the SISAQOL-IMI consortium will gather in Portugal for the third SISAQOL-IMI consensus meeting.
On 16 and 17 March, the SISAQOL-IMI consortium will convene virtually for a second consensus meeting involving all 41 members.
Patient-reported outcomes, or PROs, are important considerations when new cancer therapies are being investigated, including in benefit and risk assessments. PROs include how patients themselves experience and report their symptoms, as well as other health-related quality of life (HRQOL) issues
